ER1085 .pdf

File information


Original filename: ER1085.pdf

This PDF 1.7 document has been generated by Microsoft® Word 2016, and has been sent on pdf-archive.com on 13/08/2018 at 07:07, from IP address 92.253.x.x. The current document download page has been viewed 245 times.
File size: 829 KB (1 page).
Privacy: public file


Download original PDF file


ER1085.pdf (PDF, 829 KB)


Share on social networks



Link to this file download page



Document preview


PROGRAMA
09h30 | OPENING SESSION

13hl5 | LUNCH

Dr. Miguel Sanches

14h30 | ALK+ NSCLC: TRANSFORMING PATIENTS LIVES
09H45 | THE IMPORTANCE OF INNOVATION IN NSCLC

Chairs: Dr.3 Ana Barroso & Dr.3 Marta Soares

Chair: Jorge Correia
PhysiciarTs perspective
Prof. Dr. Antonio Araujo
Patient's perspective
Dr.3 Cristina Coelho - "Pulmonale" - Portuguese Association
for Lung Cancer

The importance of CNS preservation
in ALK+ NSCLC patients
Prof.g Dr.3 Dolores Isla

Q&A

Q&A

10h45 | DIAGNOSIS AND MOLECULAR CHARACTERIZATION
IN LUNG CANCER
Chairs: Prof. Dr. Jose Carlos Machado
& Prof. Dr. Venceslau Hespanhol
Role of molecular characterization in NSCLC management
Prof. Dr. Manuel Teixeira
The clinical benefits of Comprehensive Genomie Profiling
in lung cancer
Dr.3 Romana Wass

Q&A
11H45 | COFFEE BREAK
12H15 | LATEST DEVELOPMENTS IN THE MANAGEMENT
OF EGFR+ NSCLC

Chairs: Dr.3 Alice Pego & Dr.3 Teresa Almodóvar
Mechanism of resistance to EGFR targeted drugs
Dr.3 Paula Fidalgo
Is the treatment sequence already defined for EGFR+ patients?
Dr.g Fernanda Estevinho

Reassessing the standard of care in first linę treatment
of ALK+ NSCLC patients
Dr. Maurice Perol

15h30 | COFFEE BREAK
15h45 | IMMUNOTHERAPY: BUILDING THE FOUNDATION
FOR THE FUTURĘ
Chairs: Dr.3 Encarnaęao Teixeira
& Prof Dr. Henrique Queiroga
Immunotherapy in first-line treatment of NSCLC
Dr.3 Ana Barroso
The futurę of immunotherapy in lung cancer
Dr. Fernando Barata

Q&A
16h45 | CLOSING SESSION
17hl5 | FINAŁ REMARKS

Q&A

Roche Farmaceutica Qui'mica, Lda.
Estrada Nacional 249-1, 2720-413 Amadora
Tel.: +351 214 257 000 | Fax: +351 214 186 677 | www.roche.pt
Cont. n° 500 233 810
PT/LUN/0118/0001a, Jan 2018


Document preview ER1085.pdf - page 1/1


Related documents


er1085
esmo preceptorship on lung cancer manchester 2020 programmeocr
er1235
er1234
btog 2019 programme v7 draft
officialeventguideicieurope061118

Link to this page


Permanent link

Use the permanent link to the download page to share your document on Facebook, Twitter, LinkedIn, or directly with a contact by e-Mail, Messenger, Whatsapp, Line..

Short link

Use the short link to share your document on Twitter or by text message (SMS)

HTML Code

Copy the following HTML code to share your document on a Website or Blog

QR Code

QR Code link to PDF file ER1085.pdf